Cardiac biomarkers for assessment of acute coronary syndrome;Biomarcadores cardíacos na avaliação da síndrome coronariana aguda

Scientia Medica

Volumn 21, Issue 3, 2011, Pages 132-142

  da Silva, Sandra Huber ^a,b   Moresco, Rafael Noal ^a,c  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b Laboratório de Análises Clinicas do Hospital   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Acute coronary syndrome diagnosis; Atherosclerosis; Biological markers; Coronary disease; Inflammation; Myocardial infarction; Myocardial ischemia diagnosis; Necrosis

Indexed keywords

BIOLOGICAL MARKER; TROPONIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; BRAZIL; CARDIOVASCULAR RISK; CARDITIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; EARLY DIAGNOSIS; GOLD STANDARD; HEART DEATH; HEART INJURY; HEART MUSCLE NECROSIS; HUMAN; ISCHEMIC HEART DISEASE; PROGNOSIS; RISK ASSESSMENT;

EID: 83655202853     PISSN: 18065562     EISSN: 19806108     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Ministério da Saúde [homepage na Internet]. Datasus [citado 2010 abr 09]. Indicadores e dados básicos 2008. Taxa de Mortalidade Específica por Doenças do Aparelho Circulatório em 2006. Disponível em: http://tabnet.datasus.gov.br/cgi/deftohtm.exe?idb2008/c08.def.
2. Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002-2030. Ann Trop Med Parasitol. 2006;100:481-99.
3. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2007;50:e1-e157.
4. Piegas LS, Feitosa G, Mattos LA, et al. Sociedade Brasileira de Cardiologia. Diretriz da Sociedade Brasileira de Cardiologia sobre tratamento do infarto agudo do miocárdio com supradesnível do segmento ST. Arq Bras Cardiol. 2009;93: e179-e264.
5. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50:2173-95.
6. Nicolau JC, Timerman A, Piegas LS, et al. Diretrizes da Sociedade Brasileira de Cardiologia sobre angina instável e infarto agudo do miocárdio sem supradesnível do segmento ST (II edição, 2007). Arq Bras Cardiol. 2007;89:e89-e131.
7. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-660.
8. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008; 54:24-38.
9. Davies MJ, Thomas AC, Knapman PA, et al. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation. 1986; 73:418-27.
10. Berenshtein, E, Mayer B, Goldberg C, et al. Patterns of mobilization of copper and iron following myocardial ischemia: possible predictive criteria for tissue injury. J Mol Cell Cardiol. 1997;29:3025-34.
11. Mccord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312:159-63.
12. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. J Emerg Med. 2000;19:311-5.
13. Lippi G, Montagnana M, Salvagno GL, et al. Potential value for new diagnostic markers in the early recognition of acute coronary syndromes. CJEM. 2006;8:27-31.
14. Collinson PO, GAZE DC. Biomarkers of cardiovascular damage and dysfunction-an overview. Heart Lung Circ. 2007;16, supl. 3:S71-S82.
15. Singh V, Martinezclark P, Pascual M, et al. Cardiac biomarkers- the old and the new: a review. Coron Artery Dis. 2010;21:244-56.
16. Brogan Jr GX, Friedman S, McCuskey C, et al. Evaluation of a new rapid quantitative immunoassay for serum myoglobin versus CK-MB for ruling out acute myocardial infarction in the emergency department. Ann Emerg Med. 1994;24:665-71.
17. Britton CV, Hernandes A, Roberts R. Plasma creatine kinase isoenzyme determinations in infants and children - Characterization in normal patients and after cardiac catheterization and surgery. Chest. 1980;77:758-60.
18. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem. 2007;53:552-74.
19. Panteghini M. Diagnostic application of CK-MB mass determination. Clin Chim Acta. 1998;272:23-31.
20. Schreier T, Kedes L, Gahlmann R. Cloning, structural analysis, and expression of the human slow twich skeletal muscle/cardiac troponin C gene. J Biol Chem. 1990;265:21247-53.
21. Katus HA, Remppis A, Looser S, et al. Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. J Mol Cell Cardiol. 1989;21:1349-53.
22. Bodor GS, Porter S, Landt Y, et al. Development of monoclonal antibodies for an assay of cardiac troponin-I and preliminary results in suspected cases of myocardial infarction. Clin Chem. 1992;38:2203-14.
23. O'Donoghue M, Morrow DA. The future of biomarkers in the management of patients with acute coronary syndromes. Curr Opin Cardiol. 2008;23:309-14.
24. Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ. 2005;173:1191-202.
25. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361:858-67.
26. De Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta. 2002;317:1-15.
27. Tracy RP. Inflammation in cardiovascular disease: cart, horse, or both? Circulation. 1998;97:2000-2.
28. Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc. 2005;105:409-16.
29. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420:868-74.
30. Scirica BM, Morrow DA, Cannon CP, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007;53:1800-7.
31. Futterman LG, Lemberg L. Novel markers in the acute coronary syndrome: BNP, IL-6, PAPP-A. Am J Crit Care. 2002;11:168-72.
32. Ramos AM, Pellanda LC, Gus I et al. Marcadores inflamatórios da doença cardiovascular em idosos. Arq Bras Cardiol. 2008;92:233-40.
33. Souza JRM, Oliveira RT, Blotta MHSL, et al. Níveis séricos de interleucina-6 (IL-6), interleucina-18 (IL-18) e proteína C reativa (PCR) na síndrome coronariana aguda sem supradesnivelamento do ST em pacientes com diabete tipo 2. Arq Bras Cardiol. 2008;90:294-99.
34. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136-42.
35. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440-5.
36. Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005;51:810-24.
37. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: Part IV: Matrix metalloproteinases and biomarkers of platelet activation. Circulation. 2006;113:e382-5.
38. Creemers EE, Cleutjens JP, Smits JF, et al. Matrix metalloproteinase inhibition after myocardial Infarction: A new approach to prevent heart failure? Circ Res. 2001;89:201-10.
39. Squire IB, Evans J, Ng LL, et al. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail. 2004;10:328-33.
40. Celik T, Iyisoy A, Kardesoglu E, et al. Matrix metallo-proteinases in acute coronary syndromes: a new therapeutic target? Int J Cardiol. 2009;134:402-4.
41. Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA. 1999;96:3149-53.
42. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;345:1022-9.
43. Lund J, Qin QP, Ilva T, et al. Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation. 2003;108:1924-6.
44. Moresco RN, Bem AF, Paz da Silva JE. Circulating CD40 ligand in peripheral arterial disease. Thromb Res. 2007;120:781-2.
45. Schönbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation. 2001; 104:2266-8.
46. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-11.
47. Lee SP, Ataga KI, Orringer EP, et al. Biologically active CD40 ligand is elevated in sickle cell Anemia. Potencial role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol.2006;26:1626-31.
48. Kato K, Santana-Sahagún E, Rassenti LZ, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest. 1999;104:947-55.
49. Damas JK, Otterdal, K, Yndestad A, et al. Soluble CD40 ligand in pulmonary arterial hypertension. Possible pathogenic role of the interaction between platelets and endothelial cells. Circulation. 2004;110: 999-1005.
50. Roselli M, Mineo TC, Basili S, et al. Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res. 2004;10:610-4.t al.
51. Heeschen C, Dimmeler S, Fichtlscherer S, et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA. 2004;291:435-41.
52. Lenderink T, Heeschen C, Fichtlscherer S, et al. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47:307-11.
53. Green CJ, Lichtlen P, Huynh NT, et al. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res. 2001;61:2696-703.
54. Martín-Ventura JL, Blanco-Colio LM, Tuñón J, et al. Biomarkers in cardiovascular medicine. Rev Esp Cardiol. 2009;62:677-88.
55. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increase risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149-53.
56. Recasens M, Ricart W, Fernández-Real JM. Obesity and inflammation. Rev Med Univ Navarra. 2004;48:49-54.
57. Laimer M, Ebenbichler CF, Kaser S, et al. Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int J Obesity. 2002;26:659-62.
58. Solá E, Jover A, López-Ruiz A, et al. Parameters of inflammation in morbid obesity: lack of effect of moderate weight loss. Obes Surg. 2009;19:571-6.
59. Gonzálvez M, Ruiz-Ros JA, Pérez-Paredes M, et al. Prognostic value of tumor necrosis factor-alpha in patients with ST-segment elevation acute myocardial infarction. Rev Esp Cardiol. 2007;60:1233-41.
60. Turhan H, Erbay AR, Yasar AS, et al. Plasma soluble adhesion molecules; intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin levels in patients with isolated coronary artery ectasia. Coron Artery Dis. 2005;16:45-50.
61. Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand. 2001;173:35-43.
62. Blann AD, Lip GYH. Cell adhesion molecules in cardiovascular disease - what can soluble levels tell us? J Clin Endocr Metab. 2000;85:1745-7.
63. Gearing AJ, Newmann W. Circulating adhesion molecules in disease. Immunol Today. 1993;14:506-12.
64. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009;113:2878-87.
65. Ridker PM, Hennekens CH, Cerskus A, et al. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation. 1994;90: 2236-40.
66. Bayes-Genis A, Mateo J, Santaló M, et al. D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. Am Heart J. 2000;140:379-84.
67. Moresco RN, Vargas LC, Júnior RH, et al. Lack of association between cardiac troponin T and D-dimer in the evaluation of myocardial damage. J Clin Lab Anal. 2005;19:282-4.
68. Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis. 1981; 23:321-36.
69. Van der Vusse GJ, Van Bilsen M, Glatz JF, et al. Critical steps in cellular fatty acid uptake and utilization. Mol Cell Biochem. 2002;239:9-15.
70. Azzazy HM, Pelsers MM, Christenson RH. Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem. 2006;52:19-29.
71. Kleinfeld AM, Prothro D, Brown DL, et al. Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol. 1996;78:1350-4.
72. 3+. Eur J Biochem. 1994;220:193-200.
73. +2 binding amino-acid residues of the N-terminus of human albumin: an insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem. 2001;268:42-7.
74. Christenson RH, Duh SH, Sanhai WR, et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem. 2001;47:464-70.
75. Immanuel S, Sanjaya AI. Albumin cobalt binding (ACB) test: its role a novel marker of acute coronary syndrome. Acta Med Indones. 2006;38:92-6.
76. Da Silva SH, Hausen BS, Silva DB, et al. Characteristics of a nickel-albumin binding assay for assessment of myocardial ischaemia. Biomarkers 2010;15:353-7.
77. Sinha MK, Roy D, Gaze DC, et al. Role of " Ischemia modified albumin" , a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J. 2004;21:29-34.
78. Cichota LC, Moresco RN, Duarte MM, et al. Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal. 2008;22:1-5.
79. Kaefer M, Piva SJ, De Carvalho JA, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem. 2010;43:450-4.
80. Gottlieb MGV, Da Cruz IBM, Duarte MMF, et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab. 2010;95:586-91.
81. Roy D, Quiles J, Aldama G, et al. Ischemia Modified Albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol. 2004;97:297-301.
82. Peacock F, Morris DL, Anwaruddin S, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J.2006;152:253-62.
83. Keating L, Benger JR, Beetham R, et al. The PRIMA study: presentation ischaemia-modified albumin in the emergency department. Emerg Med J. 2006;23:764-8.
84. de Lemos JA, Morrow DA, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-21.
85. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362: 316-22.
86. Ogawa A, Seino Y, Yamashita T, et al. Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. Circ J. 2006;70: 1372-8.
87. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and risk of cardiovascular events and death. N Engl J Med. 2004;350:655-63.
88. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department. Am J Cardiol. 2005;95:948-54.
89. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357-68.